panitumumab   Click here for help

GtoPdb Ligand ID: 6883

Synonyms: ABX-EGF | ABX-EGF Mab | Vectibix®
Approved drug
panitumumab is an approved drug (FDA (2006), EMA (2007))
Compound class: Antibody
Comment: Binds to and competitively inhibits the activity of the epidermal growth factor receptor.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Used to treat EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Competitively inhibits the binding of ligands to the epidermal growth factor receptor on both normal and tumour cells. This in turn prevents the receptor autophosphorylation induced by these ligands and the activation of kinases leading to inhibition of cell growth, decreased pro-inflammatory cytokine and vascular growth factor production, and internalisation of the receptor.
External links Click here for help